<scp>DBS</scp> of Thalamic Centromedian Nucleus for <scp>Lennox–Gastaut</scp> Syndrome (<scp>ESTEL</scp> Trial)

CM-DBS in patients with LGS reduced electrographic rather than diary-recorded seizures, after 3 months of stimulation. Fifty percent of all participants had diary-recorded seizures reduced by half at the study exit, providing supporting evidence of the treatment effect. ANN NEUROL 2022;91:253-267.